Want to see IN:EMCURE full AI Analyst Report?

Emcure Pharmaceuticals Limited (EMCURE) Price & Analysis

Q: What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?

Emcure Pharmaceuticals Limited lowest stock price was ₹1260.10 and its highest was ₹2008.00 in the past 12 months.

Q: What is Emcure Pharmaceuticals Limited’s market cap?

Emcure Pharmaceuticals Limited’s market cap is ₹370.99B.

Q: When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?

Emcure Pharmaceuticals Limited’s upcoming earnings report date is Aug 06, 2026 which is today.

Q: Is Emcure Pharmaceuticals Limited overvalued?

According to Wall Street analysts Emcure Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Emcure Pharmaceuticals Limited pay dividends?

Emcure Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.15%. See more information on Emcure Pharmaceuticals Limited dividends here

Q: What is Emcure Pharmaceuticals Limited’s EPS estimate?

Emcure Pharmaceuticals Limited’s EPS estimate is 12.6.

Q: How many shares outstanding does Emcure Pharmaceuticals Limited have?

Emcure Pharmaceuticals Limited has 189,680,150 shares outstanding.

Q: Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:EMCURE

Q: What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

2 Followers

EMCURE Stock Chart & Stats

₹1345.35

₹31.90(2.25%)

At close: Jan 08 4:00 PM EST

₹1345.35

₹31.90(2.25%)

Day’s Range― - ―

52-Week Range₹1,260.10 - ₹2,008.00

Previous CloseN/A

Volume1.63K

Average Volume (3M)197.42K

Market Cap

₹370.99B

Enterprise Value₹255.38K

Total Cash (Recent Filing)₹6.02B

Total Debt (Recent Filing)₹16.59B

Price to Earnings (P/E)40.2

Beta0.76

Next Earnings

Aug 06, 2026

EPS Estimate

12.6

Next Dividend Ex-DateN/A

Dividend Yield0.15%

Share Statistics

EPS (TTM)22.89

Shares Outstanding189,680,150

10 Day Avg. Volume24,274

30 Day Avg. Volume197,417

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)6.11

Price to Sales (P/S)3.29

P/FCF Ratio61.74

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹2,100.00

Price Target Upside56.09% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)63.7

Revenue Forecast (FY)₹104.41B

Bulls Say, Bears Say

Bulls Say

Revenue And Earnings GrowthSustained FY2026 top-line expansion and meaningful EPS growth indicate durable demand for Emcure’s portfolio. Consistent revenue and earnings expansion support reinvestment in brands, scale economies and improved capital allocation, strengthening long-term competitiveness.

Operating ProfitabilityMid-teens operating margins reflect structural cost control and pricing power in key therapeutic segments. Stable operating profitability enhances cash generation potential, funds product development and commercial expansion, and provides a buffer versus generic pricing pressure.

Conservative Leverage And Improving ROELow relative debt and rising ROE point to prudent capital structure and improving capital efficiency. This financial flexibility supports selective M&A, capex for capacity or quality upgrades, and reduces refinancing risk across economic cycles.

Bears Say

Weak Cash ConversionFCF covering ~58% of net income signals earnings are not fully converting to cash, likely from working-capital drag or timing. Persistent weak cash conversion limits organic funding for capex, dividends or debt reduction and raises sensitivity to cash-cycle shocks.

Gross Margin VolatilityMaterial swings in gross margin reduce predictability of future profitability and may reflect episodic cost, mix or accounting impacts. Ongoing margin volatility complicates forecasting, risks earnings durability, and may mask underlying operational issues.

Exposure To Generic Pricing And Regulatory RiskHeavy exposure to branded generics, export market approvals and tender/partner channels subjects Emcure to price erosion and regulatory delays. These structural pressures can compress margins and make international growth lumpy without stronger differentiated IP or market exclusivity.

Emcure Pharmaceuticals Limited News

Emcure reshapes board as chairman retires and CEO takes helm

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has provided an update. Emcure Pharmaceuticals has announced a reshuffle in its...

11h ago

Emcure Pharma Files SEBI Dematerialisation Compliance Certificate

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has shared an announcement. Emcure Pharmaceuticals Limited has submitted a confirmation certificate...

1M ago

Emcure Pharmaceuticals Reports Brief Fire-Linked Shutdown at Pune Plant

The latest update is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals has reported a fire...

6M ago

Emcure Pharmaceuticals Confirms SEBI Dematerialisation Compliance for December Quarter

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) just unveiled an update. Emcure Pharmaceuticals has informed the stock exchanges that...

7M ago

Emcure Pharmaceuticals Closes Trading Window Ahead of Q3 FY2026 Results

The latest update is out from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ). Emcure Pharmaceuticals has announced the closure...

7M ago

Lilly vs. Novo Nordisk: Who Will Lead India’s Growing Obesity-Drug Market?

U.S.-based Eli Lilly & Co. ($LLY) and Danish drug maker Novo Nordisk ($NVO) are vying to capture a...

8M ago

LLY

NVO

Emcure Pharmaceuticals Allots 7,700 Shares Under Employee Stock Option Scheme

Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) has issued an announcement. Emcure Pharmaceuticals Limited has announced the allotment of...

8M ago

Emcure Pharmaceuticals Schedules Investor Conference Meeting

An update from Emcure Pharmaceuticals Limited ( ($IN:EMCURE) ) is now available. Emcure Pharmaceuticals Limited has announced its...

8M ago

EMCURE FAQ

What was Emcure Pharmaceuticals Limited’s price range in the past 12 months?

Emcure Pharmaceuticals Limited lowest stock price was ₹1260.10 and its highest was ₹2008.00 in the past 12 months.

What is Emcure Pharmaceuticals Limited’s market cap?

Emcure Pharmaceuticals Limited’s market cap is ₹370.99B.

When is Emcure Pharmaceuticals Limited’s upcoming earnings report date?

Emcure Pharmaceuticals Limited’s upcoming earnings report date is Aug 06, 2026 which is today.

How were Emcure Pharmaceuticals Limited’s earnings last quarter?

Currently, no data Available

Is Emcure Pharmaceuticals Limited overvalued?

According to Wall Street analysts Emcure Pharmaceuticals Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Emcure Pharmaceuticals Limited pay dividends?

Emcure Pharmaceuticals Limited pays a Notavailable dividend of ₹3 which represents an annual dividend yield of 0.15%. See more information on Emcure Pharmaceuticals Limited dividends here

What is Emcure Pharmaceuticals Limited’s EPS estimate?

Emcure Pharmaceuticals Limited’s EPS estimate is 12.6.

How many shares outstanding does Emcure Pharmaceuticals Limited have?

Emcure Pharmaceuticals Limited has 189,680,150 shares outstanding.

What happened to Emcure Pharmaceuticals Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Emcure Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:EMCURE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Emcure Pharmaceuticals Limited

Emcure Pharmaceuticals Limited is committed to providing high-quality, cost-effective healthcare solutions to a global market. The company boasts a diverse product lineup spanning numerous medical fields, such as women's health (gynecology), anti-infectives, pain relief, nutritional supplements (vitamins, minerals, and nutrients), hematology, oncology, respiratory treatments, HIV antivirals, gastrointestinal remedies, anti-diabetics, neurological medications, and cardiovascular therapies. Notable brand names under their umbrella include Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym. Founded in 1981, Emcure Pharmaceuticals Limited is headquartered in Pune, India.

Emcure Pharmaceuticals Limited (EMCURE) Earnings & Revenues

Historic Earnings Reports

EMCURE Stock 12 Month Forecast

Average Price Target

₹2,100.00

▲(56.09% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1304":"₹1,304","2101":"₹2,101","1503.25":"₹1,503.3","1702.5":"₹1,702.5","1901.75":"₹1,901.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.10K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1304,1503.25,1702.5,1901.75,2101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1955.85,1966.9384615384615,1978.026923076923,1989.1153846153845,2000.2038461538461,2011.2923076923075,2022.3807692307691,2033.4692307692308,2044.5576923076924,2055.646153846154,2066.734615384615,2077.8230769230768,2088.9115384615384,{"y":2100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1955.85,1966.9384615384615,1978.026923076923,1989.1153846153845,2000.2038461538461,2011.2923076923075,2022.3807692307691,2033.4692307692308,2044.5576923076924,2055.646153846154,2066.734615384615,2077.8230769230768,2088.9115384615384,{"y":2100,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1955.85,1966.9384615384615,1978.026923076923,1989.1153846153845,2000.2038461538461,2011.2923076923075,2022.3807692307691,2033.4692307692308,2044.5576923076924,2055.646153846154,2066.734615384615,2077.8230769230768,2088.9115384615384,{"y":2100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1361.24,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1378.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1305.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1318,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1431.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1403.35,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1471,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1445.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1588.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1679.95,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1704.85,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1829.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1955.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >